evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA.
Evonetix has raised €50M across 2 funding rounds from 7 investors, most recently a Series B round in Feb 2023. Based in Little Chesterford, UK; founded 2015; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-02-07 | Series B | €22M | Cambridge Consultants,Civilization Ventures,DCVC,Foresite Capital,Molten Ventures,Morningside+1 more | View deal → |
| 2020-02-03 | Series B | €27M | Foresite Capital | View deal → |
